Results 221 to 230 of about 3,722,377 (405)

PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites

Advanced Science, EarlyView.
This study demonstrates that co‐inhibition of LIN28B and PARP using siLin28b/DSSP@lip‐PEG‐FA nanoparticles in combination with the PARP inhibitor BMN673 effectively suppresses the accumulation of malignant ascites associated with advanced cancers.
Yan Fang, Qian Shen, Yao Lin, Jing Zhu, Xiaolan Zhu, Rui Huang, Yijia Wu, Feiyang Shen, Qian Li, Guopei Zheng, Zhe Zhang, Qian Chu, Junhao Hu, Jianfeng Shen   +13 more
wiley   +1 more source

Xanthogranulomatous Salpingitis Mimicking an Ovarian Tumor: A Diagnostic Challenge. [PDF]

J Midlife Health
Malakar H, Lyngdoh BS, Sinhasan SP, Newme K.   +3 more
europepmc   +1 more source

A Biomarker‐Driven Ovary–Endometrium Organ‐on‐a‐Chip Mimicking 3D Multicellular Complexity and Menstrual Cyclicity for Predicting Reproductive Toxicity

Advanced Science, EarlyView.
We present a dual‐organ, biomarker‐integrated ovaryendometrium organ‐on‐a‐chip that recapitulates 3D tissue complexity, menstrual cycle dynamics, and hormonal crosstalk. This platform enables real‐time, cell‐typespecific fluorescent readouts of reproductive toxicity using ANGPTL4 and SERPINB2 as early‐response reporters.
Soo‐Rim Kim, Eun‐kyung Min, Choon‐Mi Lee, Chan Hum Park, Byung‐Chul Oh, YunJae Jung, In‐Sun Hong   +6 more
wiley   +1 more source

Red blood cell-hitchhiking fluorescent probe to promote intraoperative diagnosis of human ovarian tumor. [PDF]

Sci Adv
Lin Y, Li K, Ding Y, Chiang ST, Xia J, Wang H, Wang H, Ai X, Feng W.   +8 more
europepmc   +1 more source

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

Nicola S. Meagher, Kylie L. Gorringe, Matthew J. Wakefield, Adelyn Bolithon, Chi Nam Ignatius Pang, Derek S. Chiu, Michael S. Anglesio, Kylie‐Ann Mallitt, Jennifer A. Doherty, Holly R. Harris, Joellen M. Schildkraut, Andrew Berchuck, Kara L. Cushing‐Haugen, Ksenia Chezar, Angela Chou, Adeline Tan, Jennifer Alsop, Ellen Barlow, Matthias W. Beckmann, Jessica Boros, David D.L. Bowtell, Alison H. Brand, James D. Brenton, Ian Campbell, Dane Cheasley, Joshua G. Cohen, Cezary Cybulski, Esther Elishaev, Ramona Erber, Rhonda Farrell, Anna Fischer, Zhuxuan Fu, C. Blake Gilks, Anthony J. Gill, Charlie Gourley, Marcel Grube, Paul R. Harnett, Arndt Hartmann, Anusha Hettiaratchi, Claus Høgdall, Tomasz Huzarski, Anna Jakubowska, Mercedes Jimenez‐Liñan, Catherine J. Kennedy, Byoung‐Gie Kim, Jae‐Weon Kim, Jae‐Hoon Kim, Kayla Klett, Jennifer M. Koziak, Tiffany Lai, Angela Laslavic, Jenny Lester, Yee Leung, Na Li, Winston Liauw, Belle W.X. Lim, Anna Linder, Jan Lubiński, Sakshi Mahale, Constantina Mateoiu, Simone McInerny, Janusz Menkiszak, Parham Minoo, Suzana Mittelstadt, David L. Morris, Sandra Oršulić, Sang‐Yoon Park, Celeste Leigh Pearce, John V. Pearson, Malcolm C. Pike, Carmel M. Quinn, Ganendra Raj Mohan, Jianyu Rao, Marjorie J. Riggan, Matthias Ruebner, Stuart Salfinger, Clare L. Scott, Mitul Shah, Helen Steed, Colin J.R. Stewart, Deepak Subramanian, Soseul Sung, Katrina Tang, Paul Timpson, Robyn L. Ward, Rebekka Wiedenhoefer, Heather Thorne, Paul A. Cohen, Philip Crowe, Peter A. Fasching, Jacek Gronwald, Nicholas J. Hawkins, Estrid Høgdall, David G. Huntsman, Paul A. James, Beth Y. Karlan, Linda E. Kelemen, Stefan Kommoss, Gottfried E. Konecny, Francesmary Modugno   +99 more
openalex   +1 more source

Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R‐Loop Accumulation and DNA Repair Deficiencies

Advanced Science, EarlyView.
ARID1A, a SWI/SNF complex component, is frequently mutated in colorectal cancer (CRC). CRC with ARID1A/TP53 concurrent mutations shows marked sensitivity to WEE1 inhibition. ARID1A loss induces R‐loop‐mediated replication stress, impairs ATF3 transcription, and amplifies WEE1i‐induced DNA damage, suggesting a promising therapeutic vulnerability ...
Chi Zhang, Yanjing Zhu, Luoyan Ai, Jingyuan Wang, Shan Yu, Yichen Wang, Xiaojing Xu, Mengling Liu, Yiyi Yu, Mengxuan Zhu, Yutong Liu, Zhenghang Xu, Haojie Zhou, Huishan Li, Qihong Huang, Qing Liu, Ke Peng, Tianshu Liu   +17 more
wiley   +1 more source

DDR2 Confers Ferroptosis Resistance to Cancer-Associated Fibroblasts and Attenuates PARPi Sensitivity of Ovarian Tumor Cells. [PDF]

Mol Cancer Res
Lesage J, DiMauro A, Schab AM, Stidham S, Mullen MM, Fuh KC, Longmore GD.   +6 more
europepmc   +1 more source

Efferocytosis‐Driven Polyamine Metabolism in Macrophages Enhances Cancer Stem Cell Enrichment after Chemotherapy in Ovarian Cancer

Advanced Science, EarlyView.
Chemotherapy‐induced efferocytosis drives ovarian cancer stem cell enrichment. By engulfing apoptotic cancer cells, macrophages upregulate ODC1 and produce putrescine, which elevates osteopontin (OPN) expression. Secreted OPN then activates the CD44 receptor on cancer cells, promoting stemness and chemoresistance.
Wenhan Li, Feiquan Ying, Xinkai Pang, Qiulei Wu, Guoqing Li, Lin Huang, Jiayu Xin, Xiaoli Liu, Pan Liu, Xiaohan Xu, Shuran Tan, Yumei Gao, Tong Liu, Si Sun, Xiaoman Wang, Yiping Wen, Liqiong Cai, Shi Du, Yuan Zhang, Jing Cai   +19 more
wiley   +1 more source

Meigs syndrome was misdiagnosed as a malignant ovarian tumor: a case report. [PDF]

Front Oncol
Li H, Xing Y, Hong W, Ma Y, Niu L.
europepmc   +1 more source

Experimental therapy against ovarian cancer by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene driven by human telomerase reverse transcriptase (hTERT) promoter

, 2011
Hongmei Li, Yuecheng Yu
openalex   +2 more sources